



Company Overview

Axogen (AXGN) is the leading Company focused specifically on the science, development, and commercialization of technologies for peripheral nerve regeneration and repair. Axogen employees are passionate about helping to restore peripheral nerve function and quality of life to patients with physical damage or transection to peripheral nerves by providing innovative, clinically proven, and economically effective repair solutions for surgeons and health care providers. Peripheral nerves provide the pathways for both motor and sensory signals throughout the body. Every day, people suffer traumatic injuries or undergo surgical procedures that impact the function of their peripheral nerves. Physical damage to a peripheral nerve, or the inability to properly reconnect peripheral nerves, can result in the loss of muscle or organ function, the loss of sensory feeling, or the initiation of pain.

Axogen's platform for peripheral nerve repair features a comprehensive portfolio of products that are used across two primary application categories: scheduled, non-trauma procedures and emergent trauma procedures. Scheduled procedures are generally characterized as those where a patient is seeking relief from conditions caused by a nerve defect or surgical procedure. These procedures include providing sensation for women seeking breast reconstruction following a mastectomy, nerve reconstruction following the surgical removal of painful neuromas, oral and maxillofacial procedures, and nerve decompression. Emergent procedures are generally characterized as procedures resulting from injuries that initially present in an ER. These procedures are typically referred to and completed by a specialist either immediately or within a few days following the initial injury.

Axogen's product portfolio includes Avance® Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; Axoguard Nerve Connector®, a porcine submucosa ECM coaptation aid for tensionless repair of severed peripheral nerves; Axoguard Nerve Protector®, a porcine submucosa ECM product used to wrap and protect damaged peripheral nerves and reinforce the nerve reconstruction while preventing soft tissue attachments; Axoguard HA+ Nerve Protector™, a porcine submucosa ECM base layer coated with a proprietary hyaluronate-alginate gel, a next-generation technology designed to provide short- and long-term protection for peripheral nerve injuries; and Axoguard Nerve Cap®, a porcine submucosa ECM product used to protect a peripheral nerve end and separate the nerve from the surrounding environment to reduce the development of symptomatic or painful neuroma. The Axogen portfolio of products is available in the United States, Canada, Germany, the United Kingdom, Spain, South Korea, and several other countries.

Board of Directors

Karen Zaderej

Chairman, Chief Executive Officer, and President

Amy Wendell

Lead Director

Guido J. Neels

Director

Gregory G. Freitag

Special Counsel

John H. Johnson

Director

Alan M. Levine

Director

Paul Thomas

Director

William Burke

Director

Joseph A. Tyndall, M.D., M.P.H

Director

Axogen, Inc.

13631 Progress Blvd
Suite 400
Alachua, FL 32615

Axogen, Inc. to Report First Quarter 2024 Financial Results and Host Conference Call on May 2, 2024

Apr 16 2024, 7:00 AM EDT

Axogen, Inc Reports 2023 Fourth Quarter and Full-Year Financial Results

Mar 5 2024, 7:00 AM EST

Axogen, Inc. to Report 2023 Fourth Quarter and Full-Year Financial Results on March 5, 2024

Feb 13 2024, 4:30 PM EST

Stock Overview

Symbol	AXGN
Exchange	Nasdaq
Market Cap	283m
Last Price	\$6.55
52-Week Range	\$3.45 - \$10.83

Investor Relations

Axogen, Inc.
13631 Progress Blvd.
Suite 400
Alachua, FL 32615
investorrelations@axogeninc.com

04/18/2024 04:00 PM EDT

Disclaimer

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.